1 / 20

APML

alfonso-baldwin
Télécharger la présentation

APML

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Under representation of bcr1 subtype of PML-RARα fusion gene in APML in Indian patientsSudha Sazawal, Syed k Hasan, Bijender Kumar, Pankhi Dutta, Rajat Kumar, Lalit Kumar*, VP Choudhry, Renu Saxena Departments of Hematology and *Medical Oncology,All India Institute of Medical Sciences, New Delhi- 29

  2. APML AML subtype: good response to ATRA Problems/ dilemma associated with APML: • Diagnosis (morphologic M2/M4 may be confused) • Response to ATRA: variable. percent

  3. Pathogenesis of APML Molecular defects • PML-RARα- t(15;17): good prognosis (99%) • (NPM) -t(5;17) – 5q35 : good prognosis • (PLZF) -t(11;17) – 11q23 • (NUMA) -t(11;17) – 11q13 Bad prognosis

  4. 10 -8 Techniques to detect t(15;17)/ PML-RARα

  5. RARa PML bcr2 bcr1 bcr bcr3 3 4 5 6 7 2 3 4 3’ 3’ 5’ 5’ A = Normal PML and RARa 3 4 5 6 3 4 3’ 5’ B = 3’ PML breakpoint (L) 3 3 4 3’ 5’ C = 5’ PML breakpoint (S) Isoforms of APML • Ambiguity exists regarding the Potential independent prognostic implications of these isoforms • bcr 1: (Long isoform) good response to ATRA • bcr 3: (short isoform) poor response to ATRA

  6. AIMS • Evaluation of role of PML-RARα in diagnosis of APML • Determination of the occurrence of breakpoint regions/ isoforms in APML in our population • Correlation with response to ATRA

  7. Material Subjects: AML patients • Inclusion criteria • Increased blasts/promyelocytes • MPO, SB, NSE/ NASDC positive • No prior chemotherapy • Exclusion criteria • Pts. received prior chemotherapy • MDS • Cytochemistry revealed MPO -ve, SB -ve Controls: ALL patients

  8. Molecular studies • RT-PCR: • RNA Extraction • Reverse transcription • Integrity assessed by β2 microglobulin • Well documented primers used (Grimwade et al 1996) • RQ/RT-PCR: for detection of PML-RARα isoforms (Cassinat et al 2000) • bcr3 • bcr1

  9. APML Management • Induction • ATRA – 45 mg/m2/ day (max. 90 days) • Inj Daunorubicin – 60mg/m2 (day 3 onwards) • Consolidation – 3 cycles • Inj Daunorubicin – 60mg/m2 • Maintenance – 2 years • ATRA – 45 mg/m2/ day x 15d (every 3 months) • 6MP – 60mg/m2/ day • MTX – 20mg/m2/ weekly

  10. AML M2 AML M3 AML M4 AML M5 AML M6

  11. RESULTS β2 microglobulin of cDNA Marker 1 2 3 4 5 6 7 8 135 bp

  12. RESULTS t(15;17)/PML-RARα PJD2A1 P1 P2 P3 P4 Marker -ve Ctrl 355 bp

  13. RESULTSPresence of PML-RARα in AML Subtypes Number of cases : 54 percent

  14. RESULTS Frequency of PML-RARα Isoforms bcr1 vs bcr3 (p=0.03)

  15. Distribution of PML-RAR Isoforms percent (p=0.004)

  16. PML-RAR Isoforms and Age

  17. PML-RARα Isoforms and median TLC Gallagher et al Blood 1997,90:1656-63 Gonzalez et al BJH 2001,114:99-03

  18. RESULTS PCR results of PML-RARα fusion transcript

  19. Conclusion • Detection of PML-RARa by RT-PCR is essential in diagnosis of AML M3 . • BCR3 Isoform is more common than BCR1 • Median WBC at presentation in Indian APMLis much higher than that in the West. • No correlation was found between WBC and Isoforms of PML-RARA

  20. Conclusion (Contd..) • No conclusive comment can be made regarding relation of bcr isoform and treatment response in this study due to small number of cases. • However, poorer response in India Vs West may be due to high WBC or bcr 3

More Related